The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

GeeCee

Forum Replies Created

Viewing 1 reply thread
  • Replies
      GeeCee
      Participant

        Thanks for all the replies. I've spent the last few hours on http://www.clinicaltrials.gov but couldn't find a study that just showed Dacarbazine vs a placebo, and none that gave response rates by age group. It seems crazy to me that the baseline chemo treatment hasn't been evaluated on its own for efficacy.

        I did find some studies that showed Dacarbazine on its own, but as the competitor for other drugs, however no breakdown by age and gender eg:

        http://www.clinicaltrials.gov/ct2/show/NCT00110994

        Anyone know how to get the detailed results or original published paper?

        either way, looking at the studies, it seems that with chemo (Bacarbazine) you are still talking a life expectancy of less than a year. Whilst if there's a response, you can expect to be progression free for a few months, the likelihood of serious adverse events is about 25%, and of other adverse events is high with a broad range of likely side effects.

        Is it worth extending life by a few months, only to have those months filled with more medical complications and misery? That's the key question.

         

        GeeCee
        Participant

          Thanks for all the replies. I've spent the last few hours on http://www.clinicaltrials.gov but couldn't find a study that just showed Dacarbazine vs a placebo, and none that gave response rates by age group. It seems crazy to me that the baseline chemo treatment hasn't been evaluated on its own for efficacy.

          I did find some studies that showed Dacarbazine on its own, but as the competitor for other drugs, however no breakdown by age and gender eg:

          http://www.clinicaltrials.gov/ct2/show/NCT00110994

          Anyone know how to get the detailed results or original published paper?

          either way, looking at the studies, it seems that with chemo (Bacarbazine) you are still talking a life expectancy of less than a year. Whilst if there's a response, you can expect to be progression free for a few months, the likelihood of serious adverse events is about 25%, and of other adverse events is high with a broad range of likely side effects.

          Is it worth extending life by a few months, only to have those months filled with more medical complications and misery? That's the key question.

           

          GeeCee
          Participant

            Thanks for all the replies. I've spent the last few hours on http://www.clinicaltrials.gov but couldn't find a study that just showed Dacarbazine vs a placebo, and none that gave response rates by age group. It seems crazy to me that the baseline chemo treatment hasn't been evaluated on its own for efficacy.

            I did find some studies that showed Dacarbazine on its own, but as the competitor for other drugs, however no breakdown by age and gender eg:

            http://www.clinicaltrials.gov/ct2/show/NCT00110994

            Anyone know how to get the detailed results or original published paper?

            either way, looking at the studies, it seems that with chemo (Bacarbazine) you are still talking a life expectancy of less than a year. Whilst if there's a response, you can expect to be progression free for a few months, the likelihood of serious adverse events is about 25%, and of other adverse events is high with a broad range of likely side effects.

            Is it worth extending life by a few months, only to have those months filled with more medical complications and misery? That's the key question.

             

        Viewing 1 reply thread